How often should you inject retatrutide? Based on Phase 2 clinical trial data, retatrutide is administered as a once-weekly subcutaneous injection, consistent with other long-acting incretin-based therapies such as semaglutide and tirzepatide. As an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, retatrutide is not currently approved in the UK and remains available only within authorised clinical trials. This article outlines the dosing schedule, injection technique, side effects to monitor, and the current regulatory status of retatrutide in the United Kingdom.

How Often Retatrutide Is Injected and Why Frequency Matters

Retatrutide is administered as a once-weekly subcutaneous injection in clinical trials, a schedule designed to maintain stable plasma drug concentrations and minimise side effects.

Retatrutide is an investigational medicine being studied for the treatment of obesity and type 2 diabetes. It belongs to a class of drugs known as triple receptor agonists, acting simultaneously on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple mechanism of action distinguishes it from existing agents such as semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP receptor agonist), and is thought to produce more pronounced effects on weight reduction and metabolic control.

Based on Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 — covering both obesity and type 2 diabetes populations — retatrutide was administered as a once-weekly subcutaneous injection within those trial protocols. This weekly dosing schedule is consistent with other long-acting incretin-based therapies and is designed to maintain stable plasma drug concentrations throughout the week, minimising peaks and troughs that could exacerbate side effects.

It is essential to emphasise that retatrutide is not approved for use in the UK and should only be used within the context of an authorised clinical trial. The dosing frequency described here reflects research protocols, not an approved prescribing regimen. Anyone participating in a trial should follow the schedule set by their clinical team precisely, including guidance on what to do if a dose is missed, rather than making independent decisions about timing or frequency.

Recommended Retatrutide Dosing Schedule and Titration Guidance

In Phase 2 trials, retatrutide was titrated from a starting dose of 0.5 mg once weekly, with incremental increases at approximately four-weekly intervals to maintenance doses of 4 mg, 8 mg, or 12 mg.

In clinical trials, retatrutide has been studied across several dose levels, with a structured titration protocol used to improve tolerability. Titration — the practice of starting at a low dose and gradually increasing it over several weeks — is a standard approach with incretin-based therapies, as it allows the gastrointestinal system to adjust and reduces the severity of nausea, vomiting, and other early side effects.

In the Phase 2 obesity trial (NEJM, 2023), participants were assigned to different dose arms with varying escalation schedules. Starting doses and escalation intervals differed across trial arms; one common approach began at 0.5 mg once weekly, with incremental increases at approximately four-weekly intervals up to target maintenance doses of 4 mg, 8 mg, or 12 mg once weekly. Not all participants started at 0.5 mg, and escalation schedules varied by protocol arm. In the 12 mg arm, participants achieved a mean body weight reduction of approximately 24% at 48 weeks — the highest observed across the dose groups — though this arm was also associated with a higher incidence of gastrointestinal side effects. Efficacy and tolerability outcomes in the type 2 diabetes Phase 2 trial were broadly consistent with these findings.

It is important to note that retatrutide does not have an approved prescribing label in the UK or elsewhere. There is no officially sanctioned dosing schedule for use outside of clinical trials. Any titration guidance currently available is derived from research protocols rather than regulatory-approved product information. If and when retatrutide receives marketing authorisation — from bodies such as the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) — a formal Summary of Product Characteristics (SmPC) will define the recommended dosing regimen. Patients should never attempt to self-titrate or source retatrutide outside of a supervised clinical trial setting.

How to Inject Retatrutide Safely and Correctly

Retatrutide is injected subcutaneously into the abdomen, thigh, or upper arm, with injection sites rotated each week and used sharps disposed of immediately in an approved sharps bin.

Retatrutide is administered by subcutaneous injection within clinical trial settings. The specific device used — whether a pre-filled pen or syringe — may vary depending on the trial protocol, and participants will receive training and written instructions from their clinical team before self-injecting. The following reflects general best-practice guidance for subcutaneous injections of this type; it does not replace trial-specific instructions or healthcare professional (HCP) training.

Recommended injection sites include:

• The abdomen (at least 5 cm away from the navel)

• The front or outer thigh

• The upper outer arm (if injecting with assistance)

Rotating injection sites with each weekly dose is important to prevent lipohypertrophy — a localised thickening of fatty tissue that can impair drug absorption. Each injection should be given into a different area within the chosen site.

Before injecting, participants should:

• Wash hands thoroughly with soap and water

• Allow the device to reach room temperature (if stored in the fridge) for the time specified in the trial instructions — typically around 30 minutes, though this may vary by device

• Inspect the solution — it should be clear and colourless; do not use if it appears cloudy or contains visible particles

• Clean the injection site with an alcohol swab and allow it to dry

• Follow the device-specific instructions provided by the trial team for needle insertion and injection technique

• Dispose of used needles and devices immediately in an approved sharps bin

Used sharps should never be placed in household waste. NHS guidance and local council schemes provide information on obtaining sharps bins and arranging safe disposal; your GP surgery, pharmacist, or clinical trial team can advise on local arrangements.

Patients should never share injection devices with others. Any concerns about injection technique should be raised with the clinical trial team or a diabetes specialist nurse before proceeding.

Side Effects to Monitor During Retatrutide Treatment

The most common side effects are gastrointestinal, including nausea and vomiting; serious concerns include pancreatitis, gallbladder disease, and hypoglycaemia in those also taking insulin or a sulfonylurea.

As with other incretin-based therapies, the most commonly reported side effects of retatrutide in clinical trials are gastrointestinal in nature. These are generally most pronounced during the dose titration phase and tend to diminish as the body adjusts to treatment.

Common side effects reported in trials include:

• Nausea (the most frequently reported)

• Vomiting

• Diarrhoea

• Constipation

• Decreased appetite

• Abdominal discomfort or bloating

These effects are largely attributable to the drug's actions on gastric emptying and gut motility. Eating smaller, lower-fat meals and avoiding rich or spicy foods can help manage nausea. Staying well hydrated is particularly important if vomiting or diarrhoea occurs, as significant fluid loss can increase the risk of dehydration and, in some cases, acute kidney injury — particularly in people taking other medicines that affect kidney function. Any persistent or severe vomiting or diarrhoea should be reported to the clinical trial team promptly.

Cardiovascular effects: Phase 2 trial data indicate that retatrutide was associated with modest increases in resting heart rate, consistent with observations seen with other GLP-1 receptor agonists. Blood pressure generally decreased in trial participants, likely reflecting the effects of weight loss. These parameters are routinely monitored in trial settings.

Additional class-related considerations based on experience with similar incretin-based medicines include:

• Pancreatitis: Seek urgent medical attention for severe or persistent abdominal pain, particularly if it radiates to the back

• Gallbladder disease: Report any yellowing of the skin or eyes (jaundice), or upper right abdominal pain

• Hypoglycaemia: People taking retatrutide alongside insulin or a sulfonylurea may be at increased risk of low blood sugar; this should be discussed with the clinical team

• Diabetic retinopathy: People with diabetes should be aware that rapid improvements in blood glucose control can occasionally be associated with changes in diabetic eye disease; discuss any visual changes with your clinical team

Thyroid considerations: Animal studies with GLP-1 receptor agonists have shown an increased incidence of thyroid C-cell tumours in rodents; however, this has not been confirmed in humans, and this is not a formal contraindication in UK or EU prescribing information for approved GLP-1 receptor agonists. As a precautionary measure, people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their clinical team before enrolment in any trial involving this drug class.

Report a lump or swelling in the neck, persistent hoarseness, or difficulty swallowing to your clinical team.

Allergic reactions: Signs of a severe allergic reaction — including rash, swelling of the face or throat, or difficulty breathing — require immediate emergency medical attention; call 999 or attend your nearest A&E department.

Participants in clinical trials should report any suspected side effects to their trial team. More broadly, suspected adverse reactions to any medicine can be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Current Availability and Prescribing Status in the UK

Retatrutide is not approved in the UK and is unavailable via the NHS or private prescription; access is only possible through participation in an authorised clinical trial.

Last updated: June 2025. Regulatory status is subject to change; readers are advised to check the MHRA (gov.uk/mhra) and EMA (ema.europa.eu) websites for the most current information.

As of the date above, retatrutide is not approved for clinical use in the United Kingdom. It remains an investigational compound, developed by Eli Lilly and Company, and is currently undergoing Phase 3 clinical trials. It has not received marketing authorisation from the MHRA, the EMA, or the US Food and Drug Administration (FDA), and therefore cannot be legally prescribed or dispensed outside of authorised clinical research settings.

This means that retatrutide is not available through the NHS, via private prescription, or through any legitimate UK pharmacy at present. Individuals who encounter websites or services offering retatrutide for sale outside of a clinical trial should exercise extreme caution — such products are unlicensed, unregulated, and potentially dangerous. The MHRA advises the public to be vigilant about purchasing medicines online and to only obtain treatments through regulated healthcare providers. Guidance on identifying legitimate online pharmacies is available at gov.uk/mhra.

For those interested in accessing retatrutide, the appropriate route is through participation in a registered clinical trial. Information about ongoing trials can be found via the ISRCTN registry (isrctn.com) and ClinicalTrials.gov. Eligibility criteria apply, and not all patients will qualify. Speaking with a specialist obesity or diabetes clinician is the recommended first step.

In the meantime, several treatments are available in the UK for obesity and type 2 diabetes management. For weight management, semaglutide (Wegovy®) is approved by the MHRA and has received a positive NICE technology appraisal recommendation for use in adults with obesity or overweight with weight-related comorbidities, subject to eligibility criteria. For type 2 diabetes, options include semaglutide (Ozempic®) and tirzepatide (Mounjaro®), both of which are once-weekly subcutaneous injections with established safety profiles and NICE guidance supporting their use in appropriate patients. Patients seeking support with weight management or metabolic health should speak with their GP or a specialist to explore currently available, evidence-based options.

Frequently Asked Questions